Progyny (PGNY) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Apr, 2026Voting matters and shareholder proposals
Election of three directors: Lloyd Dean, Kevin Gordon, and Cheryl Scott, with board recommending a vote FOR each.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026, recommended FOR by the board.
Advisory approval of executive compensation, with board recommending a vote FOR.
Approval of amendments to eliminate certain supermajority voting requirements in the certificate of incorporation, recommended FOR by the board.
Approval of amendments to eliminate default supermajority voting for certain business combinations, recommended FOR by the board.
Board of directors and corporate governance
Board recommends all director nominees for election at the annual meeting.
Proposed amendments aim to simplify governance by removing supermajority voting hurdles.
Executive compensation and say-on-pay
Advisory (non-binding) vote on executive compensation is included, with board recommending approval.
Latest events from Progyny
- Early renewals, strong sales, and new products drive growth and expand market reach.PGNY
Canaccord Genuity's 46th Annual Growth Conference - Record Q2 2026 revenue, profit, and margin growth, with strong outlook and share repurchases.PGNY
Q2 2026 - Record revenue, strong retention, and all proposals approved; poised for growth in 2026.PGNY
AGM 2026 - Robust demand, high retention, and product expansion position the business for sustained growth.PGNY
Bank of America Global Healthcare Conference 2026 - Q1 revenue up 12.2% (ex-large client), net income up 61%, and 8.8M shares repurchased.PGNY
Q1 2026 - Proxy covers director elections, auditor ratification, pay reforms, and governance changes.PGNY
Proxy filing - Key votes include director elections, auditor ratification, and reducing supermajority voting thresholds.PGNY
Proxy filing - Aiming for $2.4B+ revenue and $500M+ Adjusted EBITDA by 2028, leveraging new products and expansion.PGNY
Investor Day 2024 - Record Q1 revenue, double-digit EBITDA growth, and raised guidance amid strong demand.PGNY
Q1 2025